Riyaz Shah, Consultant Medical Oncologist at Cromwell Hospital, shared on LinkedIn:
“Lovely analysis in HER2 mutated NSCLC demonstrating that in the absence of H2H data, on balance the TKI’s have it. ADC activity maintained post TKI.
TKI good in YVMA + active in non-TKD mutations. This is a very exciting space with lots happening.”
Title: Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis.
Authors: Molly Li, Yu Yang Soon, Pui Yin Au-Yeung, Andrew Chan, Jii-Bum Lee, Jorn Nutzinger, Akiko Tateishi, Ross Soo.
You can also read: Oncogene-Driven NSCLC in 2026: Targeted Therapy Expands Across Mutations, Resistance and CNS Disease.
